Drug Profile

Nolomirole hydrochloride

Alternative Names: CHF 1035

Latest Information Update: 09 Jan 2002

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chiesi
Class Cardiotonics; Small molecules; Tetrahydronaphthalenes; Vasodilators
Mechanism of Action Alpha 2 adrenergic receptor agonists; Dopamine D2 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Heart failure

Most Recent Events

09 Jan 2002 CHF 1035 is now called Nolomirole hydrochloride
14 Nov 2000 A clinical study has been added to the Heart Failure pharmacodynamics section
20 Feb 1997 Company Communication added to the heart failure pharmacodynamics, pharmacokinetics and adverse effects sections

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com